PET/CT with fluorine-18-fluorodeoxyglucose (18F-FDG), the most commonly used radiotracer for PET neuroimaging and cancer patient management, is effective for differentiating between tumors, metastases and lymphomas in the brain and central nervous system, according to a study conducted in India and published online Sept. 15 in Nuclear Medicine Communications.

A task force convened by the International Association for the Study of Pain is warning against the use of neuroimaging in legal cases involving patients who claim they’re living with chronic pain.

Pediatric patients with nontraumatic abdominal pain are less likely to receive CT scans—and more likely to be imaged with ultrasound instead—in pediatric emergency departments than their peers taken to general emergency departments (EDs).

PET-CT with any of various radiotracers is better than conventional MRI at showing the boundaries and necrotic tissue of brain tumors and other gliomas. However, MRI is better than any flavor of PET-CT at showing the tumors’ basic anatomical structure, making the MR scans essential to initial presurgical planning.

Patients experiencing respiratory distress are not well served by lung ultrasound administered by paramedics and remotely interpreted by emergency physicians, although this could change if training techniques advance along with telemedicine and ultrasound technologies.